PDF(708 KB)
Analysis on the medication rule of traditional Chinese medicine in the treatment of COVID-19 patients
Xiaoyu Tan, Qingqing Yang, Xianming Cai, Yiming Tao, Suyu Gao, Lixia He, Yubin Zhao, Siyan Zhan, Hong Cheng, Haibo Song, Feng Sun
PDF(708 KB)
PDF(708 KB)
Analysis on the medication rule of traditional Chinese medicine in the treatment of COVID-19 patients
Objective: To describe patterns of utilization of traditional Chinese medicine (TCM) in the treatment of patients with coronavirus disease 2019 (COVID-19).
Methods: Adult patients with COVID-19 who received TCM treatment were divided into a non-serious group (mild and moderate types) and a serious group (severe and critical types) according to their admission conditions. The medical records and prescriptions of these patients were investigated to determine their TCM utilization patterns.
Results: In all, 3,872 COVID-19 patients were included. Oral Chinese traditional patent medicine (CPM) was the most commonly used type of TCM, followed by decoction. The proportion of multi-drug combinations was higher than single drug use (55.0% vs. 45.0%). Decoction combined with oral CPM was the most common combination (39.1%, 1,514/3,872). Orally administered, injected, and externally applied CPM were significantly more common in the serious group than in the non-serious, while decoction and non-drug TCM treatments were more common in the non-serious than in the serious group. Multi-drug combinations were used for the majority of patients in both groups, mainly in the form of decoctions combined with oral CPM. Among the serious patients, injected CPM was more often used in patients who died during treatment (35.0%, 36/103). The two most common medication patterns were decoction combined with oral CPM and oral CPM alone in the two finally discharged groups. Oral CPM alone or used in combination with injected CPM were seen most commonly in the death group. Significant differences were established in TCM utilization and medication patterns among patients in three groups who had different prognoses and outcomes.
Conclusions: The treatment measures and medication patterns of TCM commonly used in COVID-19 patients with the range of conditions found in this study should be further explored in the future to provide a more complete reference for COVID-19 treatment.
COVID-19 / Descriptive analysis / Drug utilization / Medication pattern / Traditional Chinese medicine (TCM)
| [[1]] |
National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine. Diagnosis and treatment plan for COVID-19 (trial version 8 revision). Chin J Clin Infect Dis 2021;14(2):81-88.
|
| [[2]] |
WHO. WHO Director-General's opening remarks at the media briefing on COVID-19.(2020-03-11)[2021-07-28].
|
| [[3]] |
WHO. Coronavirus disease (COVID-19) pandemic.(2020-1-20) [2021-11-17].
|
| [[4]] |
MSD. MSD and Ridgeback announce Japanese Government to purchase 1.6 million courses of Molnupiravir, an investigational oral COVID-19 antiviral medicine, upon authorization or approval. (2020-05-20)[2021-11-17]
|
| [[5]] |
Pfizer. Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 epic-hr study. (2021-11-12)[2021-11-17].
|
| [[6]] |
WHO. Therapeutics and COVID-19: living guideline. (2020-9-02) [2021-11-17].
|
| [[7]] |
National Institutes of Health (US). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. (2021-04-21)[2021-11-17].
|
| [[8]] |
General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment plan for pneumonia caused by novel coronavirus infection (trial version 3). Tianjin J Tradit Chin Med 2020;37(1):1-3.
|
| [[9]] |
Chen Y, Su TS, Song QQ. An overall analysis of non-drug intervention programs for COVID-19. J Shaanxi Univ Chin Med 2020;43(4):19-25. 34.
|
| [[10]] |
The State Council Information Office of the People's Republic of China. White Paper on China's Actions against COVID-19 (full text). (2020-06-07)[2021-07-21].
|
| [[11]] |
Hu K, Guan WJ, Bi Y, et al.Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine 2021;85:153242.
|
| [[12]] |
Liu X, Song Y, Guan W, et al.A multicenter prospective cohort study of Xuebijing injection in the treatment of severe coronavirus disease 2019. Chin Crit Care Med 2021;33(7):774-778.
|
| [[13]] |
Zhang L, Zheng X, Bai X, et al.Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: a national retrospective registry study. Phytomedicine 2021;85: 153531.
|
| [[14]] |
Yuan D, Zheng ZY, Zhuang S, et al. Primary study on TCM syndrome, diagnosis and treatment of children infected with COVID-19 Delta strain in Putian, Fujian in 2021. Fujian J Tradit Chin Med 2021;52(10):1-2+5.
|
| [[15]] |
General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of corona virus disease-19 (7th trial edition). China Med 2020;15(6):801-805.
|
| [[16]] |
Zhao KQ, Zhang YX, Zheng FJ.On Wu Youke's theory of epidemic disease and characteristics of diagnosis and treatment. Global Tradit Chin Med 2021;14(3):417-420.
|
| [[17]] |
Jin G, Jin LL, Jin BX.The rationale behind the four major anti- COVID-19 principles of Chinese herbal medicine based on systems medicine. Acupunct Herb Med 2021;1(2):90-98.
|
| [[18]] |
Wang JC, Lin LY, Li BT, et al.Research progress on prevention and treatment of coronavirus disease 2019 (COVID-19) with traditional Chinese medicine. J Shenyang Pharm Univ 2021;38(7):751-761.
|
| [[19]] |
Wang K, Yan HY, Wu S, et al.Inhibitory effect of Qing-Fei-Pai-Du decoction on coronavirus in vitro. Acta Pharm Sin 2021;56(5):1400-1408.
|
| [[20]] |
Li RF, Hou YL, Huang JC, et al.Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARSCoV- 2). Pharmacol Res 2020;156:104761.
|
| [[21]] |
He LL, Gong PY, Feng Y, et al.Analysis on application of Chinese materia medica in treatment of COVID-19 by suppressing cytokine storm. Chin Tradit Herbal Drugs 2020;51(6):1375-1385.
|
| [[22]] |
Dai YJ, Jiang L, Gao JR, et al. Study on COVID-19 mechanism of Xuebijing injection by network pharmacology and molecular technology. Chin J Hosp Pharm 2020;40(21):2233-2237+2275.
|
| [[23]] |
Guo PF, Fang JS, Xu JL, et al.The molecular mechanism of Huashi Baidu decoction in the treatment of COVID-19 based on network pharmacology and molecular docking technology. Modern Tradit Chin Med Mater Med-World Sci Tech 2021;23(4):1048-1062.
|
| [[24]] |
Tu H, Tu S, Gao S, et al.Current epidemiological and clinical features of COVID-19: a global perspective from China. J Infect 2020;81(1):1-9.
|
| [[25]] |
Wang CC, Wu S, Jiang LJ, et al.Comprehensive analysis of TCM diagnosis and treatment schemes for COVID-19 in all regions of China. Modern Tradit Chin Med Mater Med-World Sci Tech 2020;22(2):257-263.
|
| [[26]] |
Duan C, Xia WG, Zheng CJ, et al.Clinical observation on Jinhua Qinggan granule combined with conventional western medicine therapy in treating mild cases of coronavirus disease 2019. J Tradit Chin Med 2020;61(17):1473-1477.
|
| [[27]] |
Fan Z, Guo G, Che X, et al.Efficacy and safety of Lianhuaqingwen for mild or moderate coronavirus disease 2019: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2021;100(21): e26059.
|
| [[28]] |
Liu XS, Song YL, Guan WJ, et al.Multi-center prospective cohort study of Xuebijing injection in the treatment of severe COVID-19. Chin Critical Care Med 2021;33(7):774-778.
|
| [[29]] |
Wen L, Zhou Z, Jiang D, et al.Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019. Chin Critical Care Med 2020;32(4):426-429.
|
| [[30]] |
Zeng WJ, Dong Q, Ren YX, et al.Overview of famous TCM prescriptions and medicines for the prevention and treatment of COVID-19. Tradit Chin Med Res 2021;34(7):62-67.
|
| [[31]] |
Han X. “Three drugs and three prescriptions” was screened for COVID-19 treatment. (2020-03-24)[2021-07-26].
|
| [[32]] |
Xu WT. Traditional Chinese medicine has its own way to fight epidemic! Experts reveal why the “three drugs and three parties” is excellent. Lifetimes. (2020-03-26)[2021-09-28].
|
| [[33]] |
Xiao JF, Jin Y.Investigation on rationality of Chinese patent medicine use in outpatient department of our hospital in 2019. J Tradit Chin Med Manage 2021;29(14):89-91.
|
| [[34]] |
Sun QG, An XD, Xie P, et al.Traditional Chinese medicine decoctions significantly reduce the mortality in severe and critically ill patients with COVID-19: a retrospective cohort study. Am J Chin Med 2021;49(5):1063-1092.
|
| [[35]] |
Qin LX, Lyu WL, Yang M, et al.Clinical characteristics, drug treatments and prognoses in 605 patients with severe and critical corona virus disease 2019 in Hubei, China: a multi-center, retrospective, cohort study. Chin Archives Tradit Chin Med 2021;39(3):89-95.
|
| [[36]] |
General Office of the National Health Commission, Office of National Administration of Traditional Chinese Medicine. Guidelines for diagnosis and treatment of severe cases with novel coronavirus pneumonia. Chin J Viral Dis 2020;10(3):161-163.
|
| [[37]] |
Zhang XY, Lyu L, Zhou YL, et al.Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial. Phytother Res 2021;35(8):4401-4410.
|
| [[38]] |
Ma Q, Xie Y, Wang Z, et al.Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2. J Ethnopharmacol 2021;279:114367.
|
| [[39]] |
Zhang X, Xue Y, Chen X, et al.Effects of Tanreqing capsule on the negative conversion time of nucleic acid in patients with COVID- 19: a retrospective cohort study. J Integr Med 2021;19(1):36-41.
|
| [[40]] |
Xu X, Zhang J, Zheng W, et al.Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study. Ann Palliat Med 2021;10(5):5146-5155.
|
| [[41]] |
Kim DS, Chu H, Min BK, et al.Telemedicine Center of Korean Medicine for treating patients with COVID-19: a retrospective analysis. Integr Med Res 2020;9(3):100492.
|
| [[42]] |
Zeng XY, Zhou QX, Zhang JX, et al.Efficacy of treatments for b-coronaviruses associated respiratory diseases: a systematic review . Chin J Evidence-Based Med 2021;21(9):1055-1066.
|
| [[43]] |
Liu DH, Liang BZ, Huang LY.Clinical observation on the preventive effect of Kangdu Bufei decoction on acute severe respiratory syndrome. Chin J Integr Tradit West Med 2004;(8):685-688.
|
| [[44]] |
Luo H, Tang QL, Shang YX, et al.Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med 2020;26(4):243-250.
|
| [[45]] |
Zhan M, Bin DH, Liu B, et al.Brief analysis of the prescriptions for preventing COVID-19 in children and old people: take the Hunan Province COVID-19 Prevention Formular II as an example. J Hunan Univ Chin Med 2021;41(6):944-947.
|
| [[46]] |
Li JC, Li SY, Gu J, et al.Review and reflection on the prevention of COVID-19 by traditional Chinese medicine based on the theory of preventive treatment of disease. Chin Med Mat 2021;(4):1021-1030.
|
| [[47]] |
Chen JM, Lian B, Chen TF, et al.The development strategy of TCM acute and critical care medicine from the status of diagnosis and treatment of new coronary pneumonia by TCM. Lishizhen Med Mater Med Res 2021;32(2):388-393.
|
| [[48]] |
Liu B, Chen B, Guo Y, et al.Acupuncture - a national heritage of China to the world: international clinical research advances from the past decade. Acupunct Herb Med 2021;1(2):65-73.
|
/
| 〈 |
|
〉 |
AI Summary
